E7 is the major transforming protein of human papillomavirus (HPV), which is implicated in the development of cervical cancer. The transforming activity of E7 has been attributed in part to its interaction with the retinoblastoma (Rb) tumour suppressor; however, the Rb interaction alone is not sucient for transformation by E7. In a screen for cellular targets of HPV E7, we identi®ed the Ski interacting protein, Skip, as a new interacting partner of E7. We show that HPV-16 E7 associates with Skip via sequences in its carboxy terminal region, and the evolutionarily conserved proline rich sequences (PRS) of the SNW domain of Skip. E7 functionally targets Skip in vivo and inhibits its transcriptional activation activity. Two transformation defective mutants of E7 were identi®ed that failed both to bind Skip and to inhibit its transcriptional activity. These results suggest that inhibition of Skip function may contribute to cell transformation by HPV-16 E7. Oncogene (2001) 20, 7677 ± 7685.
Introduction
Human papillomavirus (HPV) is implicated as a causative agent in the aetiology of cervical dysplasia and cervical cancer. High-risk HPV-16 and HPV-18 are frequently detected in malignant tumours and are associated with the majority of cervical carcinomas (zur Hausen and Schneider, 1987) . In contrast, low risk HPV-6 and HPV-11 are associated with benign genital warts and are very rarely detected in tumours. The virus encodes two major oncoproteins, E6 and E7, both of which are continually retained and expressed in cervical tumours Banks et al., 1987; Smotkin and Wettstein, 1986) . In addition, coexpression of HPV-16 E6 and E7 has been shown to be sucient to immortalize primary human keratinocytes (Hawley-Nelson et al., 1989; MuÈ nger et al., 1989) , the natural host cells for papillomavirus infection in vivo. The E6 and E7 proteins act cooperatively by interfering with the functions of the cellular tumour suppressor proteins, p53 and pRb respectively (Dyson et al., 1989; Werness et al., 1990) . Of the two HPV oncoproteins, E7 is considered to be the major transforming protein and is structurally and functionally similar to adenovirus E1A and SV40 Large T antigen. Based on these similarities, E7 can be divided into three domains: the amino-terminal conserved region 1 (CR1), CR2 containing an LXCXE Rb binding motif, and a carboxy-terminal zinc ®nger (CR3). Functionally, the CR2 portion of E7 associates with pRb and interferes with its binding to E2F (Chellappan et al., 1992) . The E7/Rb interaction leads to the release of E2F from the pRb-E2F complex, which subsequently activates genes essential for progression through late G1 and S phase, including those necessary for DNA replication and cell cycle regulation (reviewed in Jansen-DuÈ rr, 1996) .
Several ®ndings suggest, however, that pocket proteins are not the only cellular targets of E7 required for its transforming activity. For example, a pRb binding-defective mutant of E7 can still immortalize primary human keratinocytes in cooperation with E6 (Jewers et al., 1992) . In addition, deletion mutants of either CR1 or the carboxyl-terminal region of E7 markedly reduce its transforming capacity, while still retaining the ability to bind pRb (Edmonds and Vousden, 1989; Watanabe et al., 1990; Barbosa et al., 1990; Banks et al., 1990; Massimi et al., 1997) . Finally, a recent study has demonstrated that HPV E7's stimulation of proliferation does not correlate directly with pRb binding (Caldeira et al., 2000) . These observations imply that regions outside the Rb-binding domain must be important for the transforming potential of HPV-16 E7. However, how these regions contribute to transformation is poorly understood.
In an attempt to discover new cellular target proteins of E7, we performed a two-hybrid screen, using HPV-16 E7 as a bait, and we have now identi®ed Skip (Ski interacting protein) as a new interacting partner for E7. Skip was originally identi®ed as a binding partner of the viral oncogene, v-Ski (Dahl et al., 1998) , and Skip has recently been shown to possess the characteristics of a transcriptional co-activator on a number of cellular promoters (Baudino et al., 1998; Zhou et al., 2000) . Using a variety of assays, we show a strong and direct interaction between HPV-16 E7 and Skip. Mutants of E7 have been identi®ed which fail to interact with Skip, and these also exhibit reduced transforming activity. The binding site of E7 has been mapped to a proline rich sequence (PRS) within Skip's highly conserved SNW domain, suggesting that this is a functionally important region of the protein. Finally, we show that as a consequence of this interaction, E7 antagonizes Skip's coactivator activity.
Results

Identification of Skip as a new interacting partner of HPV-16 E7
We used a yeast two-hybrid assay to identify novel cDNA clones that code for proteins which interact with the HPV-16 E7. The HPV-16 E7 oncoprotein was fused in-frame to the GAL4 DNA binding domain in the vector pAS1, and this was used to screen a lymphoid cDNA library that was constructed in pACT (Durfee et al., 1993) . The two-hybrid screen with E7 identi®ed three clones of the same cDNA clone encoding Skip, which was originally identi®ed as a v-Ski-interacting protein (Dahl et al., 1998) . To further con®rm a speci®c interaction of Skip with HPV-16 E7, the isolated clones (pACT-Skip) were rescued in E. coli and retransformed into yeast containing pAS-E7 and selected E7 mutants, together with additional GAL4-DNA binding domain fusion constructs as controls. The results of the bgalactosidase assay from the back-screenings are shown in Figure 1 . The pAS-16 E7 did not show any interaction with pACT alone, but again showed strong interaction with pACT-Skip. Speci®city controls included testing pACT-Skip against pAS-HPV-18 E6, pAS-HPV-18 E2 and the pAS1 parental vector. Both pAS-HPV18 E6 and pAS-HPV18 E2 which had been used earlier as baits in two-hybrid screens (KuÈ hne and Banks, 1998) , failed to show any interaction with Skip. The ability of the low risk type HPV-11 E7 protein (pAS-11 E7) to interact with Skip was also assessed and as can be seen, the interaction was signi®cantly weaker than that with HPV-16 E7 (Figure 1) .
In order to identify the region of HPV-16 E7 required for the interaction with Skip, two deletion constructs of E7, encompassing amino acids 1 ± 42 and 27 ± 97, were also included in this assay. As can be seen from Figure 1 , the amino-terminal region of E7 (amino acids 1 ± 42) did not show any interaction, whereas the carboxy terminal portion (amino acids 27 ± 97) showed wild type levels of interaction. This implies that the portion of E7 from amino acid 27 onwards is important for the interaction with Skip.
The interaction between HPV-16 E7 and Skip is direct
To further con®rm the speci®city of the E7/Skip interaction observed in yeast, we ®rst performed in vitro GST pull-down assays. Bacterially expressed GST or GST-16 E7 fusion proteins were immobilized on glutathione-agarose and were then mixed with in vitro translated 35 S-methionine-labelled Skip protein. After extensive washing, the bound proteins were analysed by SDS ± PAGE and autoradiography. As shown in Figure  2 , approximately 25% of input Skip protein was speci®cally retained on the E7-conjugated agarose beads, further con®rming the validity of the interaction seen in yeast. However, neither the in vivo interaction in yeast nor the GST-pull down assay using in vitro translated Skip rules out the possibility that this interaction occurs via an intermediate protein.
To investigate this, HPV-16 E7 was expressed as a six histidine-containing fusion protein (His 6 ) and puri®ed by Ni 2+ -NTA agarose column chromatography. A GST-pull down assay was then performed using recombinant His 6 -16 E7 with GST or GST-Skip fusion protein. Following extensive washing, the amount of E7 retained was determined by electrophoresis and Western blotting with an anti HPV-16 E7 antibody. The results obtained are shown in Figure  3 . As can be seen, quantitative recovery of the E7 protein was obtained on the GST-Skip agarose resin (lanes 2 and 3), whereas no binding to GST alone (lane 1) was detected. The direct interaction between recombinant His 6 -16 E7 and GST-Rb served as a positive control (lane 4). These results demonstrate that the interaction between E7 and Skip is direct and is not mediated by any other protein.
HPV E7 abrogates the transactivation function of a Skip+Ski complex
Previous reports have shown that Skip can activate expression from a number of dierent promoters (Baudino et al., 1998; Zhou et al., 2000) . In our hands, this appears to be a general activity of Skip that is augmented by the presence of cellular Ski (Prathapam et al., 2001) . Given the physical interaction between E7 and Skip, we next measured the eect of E7 expression on the transcriptional activation activity of a Skip-Ski complex on the HSV TK promoter in U2OS cells. As can be seen in Figure 4 , increasing amounts of HPV-16 The plasmid pAS1 contains a GAL4 DNA binding domain, whereas the plasmid pACT contains the VP16 activation domain. The plasmid designated pACT-Skip was isolated in the interaction screen using HPV-16 E7 as bait. The strength of interaction was analysed by b-galactosidase assay and shows the results from a representative back-screening assay of wild type E7, two E7 deletion mutants and HPV-11 E7, HPV-18 E6 and HPV-18 E2 with the pACT-Skip HPV-16 E7 oncoprotein binds Skip T Prathapam et al E7 induce a dose-dependent inhibition of the Skip-Ski transactivation activity. In contrast, a parallel assay using the E7 responsive AdE2 promoter, in the presence of E7 alone, showed marked transcriptional transactivation, in agreement with previous observations (Phelps et al., 1988) , demonstrating the functionality of the E7 protein used in the assay. In order to determine whether pRb was involved in this activity of E7, the transcriptional inhibition assay was performed in Saos-2 cells, which lack any functional pRb. In this case the AdE2 promoter was used, which is unresponsive to E7 in these cells due to this lack of pRb. As can be seen from Figure 5 , increasing amounts of E7 again dramatically suppressed the transactivation activity of the Skip-Ski complex. These results demonstrate that one consequence of the E7-Skip interaction is the inhibition of the ability of Skip to activate the expression from certain target promoters.
Identification of the Skip binding domain on HPV-16 E7
To determine whether the ability of E7 to bind and inactivate Skip transactivation might be relevant for its oncogenic potential, several transformation-defective mutants of E7 were analysed for their ability to interact with Skip. The structure of the HPV-16 E7 and the mutants used in the study are shown schematically in Figure 6a . We ®rst performed GSTpull down assays using in vitro translated, 35 Smethionine-labelled Skip protein, together with GSTmutant E7 fusion proteins. As can be seen in Figure  6b , GST-16 E7 wild type was able to bind Skip with high anity, whereas GST alone did not. However, both the amino terminal mutants, p24Gly (pRb binding defective) and p2Pro showed wild type binding anity, con®rming that the interaction is not through the amino-terminal region of 37 and is independent of the pRb/E7 interaction. In contrast, mutants p31/32 and D52-56 showed little or no binding with Skip ( Figure 6c ). The p31/32 lies within the CKII phosphorylation site in E7 and D52-56 is a small deletion within the carboxy terminal loop. Both mutants exhibit greatly reduced transforming activity (Barbosa et al., 1990; Massimi et al., 1997) , suggesting that this interaction with Skip may contribute to E7's oncogenic activity.
Having shown that HPV-16 E7 abrogates the transactivation function of a Skip-Ski complex and having identi®ed mutants of E7 which fail to interact with Skip, we next proceeded to investigate whether inhibition of Skip+Ski-mediated transactivation was dependent upon the ability of E7 to bind Skip. Transcriptional activation assays were done in U2OS Figure 2 Interaction of HPV-16 E7 with Skip in vitro. A GSTpull down assay was performed by incubating puri®ed GST-E7 protein with in vitro translated Skip together for 1 h at room temperature. After extensive washing bound proteins were analysed by SDS ± PAGE and autoradiography (a). (b) shows the Coomassie Blue stain of the gel used in the binding assay Figure 3 The interaction between E7 and Skip is direct. GSTSkip and GST-Rb fusion proteins and GST alone were puri®ed on glutathione agarose columns. These were then incubated with 40 ng of recombinant puri®ed His 6 -16 E7 at room temperature for 1 h. After extensive washing bound E7 was assessed by SDS ± PAGE and Western blot analysis with an antiserum raised against HPV-16 E7. Panel B shows the Ponceau protein stain of the membrane used in the binding assay cells using the HSV TK CAT reporter. As shown in Figure 7 , wild type E7 strongly repressed the Skip+Ski-mediated transactivation of this promoter. Interestingly, the p31/32 mutant failed to suppress Skip activation of the HSV TK promoter. Likewise, mutant D52-56 was also reduced in its ability to repress the Skip+Ski mediated trans-activation. These results demonstrate that the mutants of E7 that are unable to bind Skip, are also defective in their ability to repress Skip-Ski transactivation. This suggests that suppression of Skip transcriptional activity by E7 is a consequence of E7's ability to bind Skip.
Identification of the E7 binding motif on Skip
Having identi®ed Skip as a functional target of E7, we next wanted to identify the potential motifs of Skip involved in the interaction with E7. Therefore, we ®rst made a series of Skip deletion constructs, and these are shown schematically in Figure 8a . The various Skip deletion mutants were translated in vitro and labelled with 35 S-methionine. GST-pull down assays were done using GST-16 E7 fusion protein bound to glutathioneagarose. The results obtained are shown in Figure 8b ,c. As can be seen, wild type (wt) Skip showed strong binding to GST-16 E7 (Figure 8b, lane 1) . In addition, mutant 1 ± 353 showed wt levels of interaction (lane 2), whereas the carboxy terminal mutant containing amino acid residues 350 ± 536, and the amino terminal mutant containing amino acids 1 ± 179 failed to bind (lanes 3 and 4). Interestingly, the mutant comprising the amino acids 220 ± 398 retained substantial binding in the GST-pull down assay (lane 5), suggesting that this region is important for the interaction with the 16 E7. To further de®ne the E7 binding motifs of Skip, additional deletion constructs of Skip were made and GST-pull down assays were done, and the results obtained are shown Figure 8c Most interestingly, the mutant 1 ± 236, which contains the proline rich sequence (PRS), retained wild type levels of binding (lane 4), thus demonstrating that the PRS is the region of Skip bound by E7. Mutant 1 ± 292, which also contains the PRS, also showed wild type binding activity to E7 (lane 5). These results suggest that E7 binding to Skip's PRS is responsible for E7 abolition of Skip+Ski-mediated transcriptional activation. Results from a representative GST pull down assay with the E7 amino-terminal mutants. Puri®ed GST fusion proteins on glutathione resin were incubated with the in vitro translated Skip for 1 h at room temperature. After extensive washing bound proteins were analysed by SDS ± PAGE and autoradiography. (c) Results from a representative GST pull down assay from the E7 carboxy-terminal mutants. The lower panels of (b) and (c) show the Coomassie Blue stain of the gels used in the binding assay
Discussion
A number of studies have suggested that HPV-16 E7 plays a critical role in the development of cervical cancer by inactivating pRb. However, a large amount of evidence has indicated that inactivation of pRb is necessary, but not sucient, for transformation (Edmonds and Vousden, 1989; Banks et al., 1990; Watanabe et al., 1990; Jewers et al., 1992) , suggesting that in addition to pRb, other cellular targets of E7 are required for its full transforming activity. It is shown here that the E7 protein targets Skip, a recently identi®ed transcriptional coactivator. Expression of E7 in vivo in mammalian cells inhibits the transcriptional activation mediated by the Skip+Ski complex in a dose-dependent fashion. These results identify Skip as a new cellular target for HPV-16 E7.
Skip was initially identi®ed as an interacting protein of v-Ski, an oncogene of avian Sloan Kettering viruses (Dahl et al., 1998) , which was found to transform chicken embryo ®broblasts (Stavnezer et al., 1981) . Interestingly, Skip was found to interact with a highly conserved region of Ski that is required for its transforming activity (Dahl et al., 1998) . The transforming activity of v-Ski is due to its interaction with the pRb tumour suppressor protein and consequent inhibition of pRb-mediated transcriptional repression (Tokitou et al., 1999) . Since E7 shares many properties with the viral oncogene v-Ski, the biological signi®cance of the E7/Skip interaction was of obvious interest. Furthermore, Skip has also been shown to be essential for the Epstein-Barr virus-encoded latency protein (EBNA2)-mediated immortalization of B-lymphocytes (Zhou et al., 2000) . Skip interacts with the CR5 of EBNA2, which is important for its transforming activity and is shown to play a role in EBNA2 activation of CBF1-repressed promoters (Zhou et al., 2000) .
The interaction of E7 with Skip was ®rst identi®ed using a yeast two-hybrid screen. This was con®rmed ®rst by GST-pull down assays using in vitro translated Skip and then by a direct interaction assay using recombinant His 6 -16 E7. The weak interaction of non-oncogenic HPV-11 E7 with Skip suggested that HPV-16 E7's interaction with Skip might be high risk virus speci®c, and hence related to its oncogenic function. This was con®rmed by a mutational analysis of E7 using a number of transformation-defective mutants of E7. The ability of E7 to interact with Skip was drastically reduced when mutations were introduced either in the CKII recognition site (mutant p31/32) or in the C-terminus of E7 (D52 ± 56). Both mutants are also severely reduced in their ability to transform cells. Similarly, the ability of E7 to inhibit Skip+Ski-mediated transactivation is impaired by the same deletion mutants, although D52 ± 56 retains some activity in this assay, suggesting that there may be residual Skip binding activity in vivo. These ®ndings raise the possibility that the ability of E7 to abrogate the function of Skip may contribute to its transforming activity. Another transformation-defective mutant, p24Gly, which is impaired for binding pRb (Edmonds and Vousden, 1989) , is able to bind Skip with the same anity as wt E7, suggesting that the eects of E7 on Skip are not mediated via pRb. This further supports the hypothesis that many distinct regulatory pathways must be subverted by E7 in order to transform mammalian cells.
Finally, a deletion analysis of Skip identi®ed the PRS/SNW domain of Skip as being the region bound by E7. This region of Skip is evolutionarily highly conserved (Dahl et al., 1998) and suggests that E7 is targeting a functionally important domain of the protein. Since one consequence of the interaction between E7 and Skip is abrogation of Skip's transcriptional activity, this suggests that the PRS/SNW domain of Skip may also be required for its transcriptional activity. Studies are currently in progress to investigate this further.
In summary, we have identi®ed Skip as a new cellular target of HPV-16 E7. E7 functionally inhibits the transcriptional activation activity of Skip by directly binding to the PRS domain of Skip. Mutants of E7 which fail to interact with Skip are greatly reduced in their ability to transform cells, suggesting that this interaction is important for its transforming activity.
Materials and methods
Yeast two-hybrid screen
The yeast two-hybrid system was used to screen a human lymphoid cell library (Durfee et al., 1993) . Full-length HPV-16 E7 was cloned in frame with pAS1-GAL4 and was used as bait. Approximately 2610 7 transformants were plated onto the synthetic complete (SC) medium lacking tryptophan, leucine, and histidine, but containing 25 mM 3-amino-triazole (Sigma) for selection. Selected colonies were then analysed in a b-galactosidase assay. For con®rmation of the screen, the plasmids from 3-amino-triazole-resistant and b-galactosidase positive colonies were rescued in Escherichia coli DH5a and retransformed into S. cerevisiae Y187, which were then crossed with S. cerevisiae Y190 containing pAS-GAL4 fused deletion mutants of E7. These crosses were analysed by bgalactosidase assay as described previously (KuÈ hne and Banks, 1998).
Plasmids
To construct yeast expression plasmids containing GAL4-E7 fusion genes, E7 speci®c primers were used in a PCR reaction to amplify E7 sequences from pJ4O16E7 and pJ4O11E7 (Storey et al., 1988) . PCR products were digested with BamHI and SalI and ligated in frame with the GAL4 DNA-binding domain of the yeast expression vector pAS1 (Durfee et al., 1993) . Vectors expressing GST-fusion proteins of E7 were constructed by ligating the PCR products into the vector pGEX 2.0. GST-Skip was constructed by subcloning the Skip from the original library plasmid pACT-Skip into the vector pGEX 3X at the Figure 8 Mapping the HPV-16 E7 interaction domain on Skip. (a) A schematic diagram of the Skip deletion mutants used in the analysis. Numbers refer to the amino acid residues and the central boxed region corresponds to the highly conserved SNW region where homology with Skip proteins derived from other species is greater than 90%. The relative strength of binding of each protein to E7 is also shown, together with the mean percentage binding from at least three separate assays, where +++ and +/7 indicates 20 ± 30% and 3 ± 5% binding respectively. (b,c) Results from representative GST pull-down assays. Puri®ed GST or GST-E7 on glutathione resin were incubated with the in vitro translated Skip deletion mutants for 1 h at room temperature. After extensive washing bound proteins were analysed by SDS ± PAGE and autoradiography. Lower panels of (b) and (c) show the Coomassie Blue stain of the gels used in the binding assay BamHI site. GST-Rb has been described previously (Quin et al., 1992) . The dierent Skip expression plasmids used in this study were cloned into the BamHI/EcoRI sites of pcDNA 3.1, by PCR ampli®cation from pCGSP-Skip, kindly provided by MJ Hayman (Dahl et al., 1998) . These constructs were veri®ed by DNA sequencing using the dideoxy chain termination method (Sanger et al., 1977) and were used for in vitro translations. The cellular Ski expression plasmid, pMT2-Ski, was kindly provided by MJ Hayman (Dahl et al., 1998) . CAT reporter constructs pBLCAT2 and AdE2CAT have been described previously (Luckow and Schutz, 1987; Murthy et al., 1985) . For making His 6 -16 E7, the gene was cloned in pET7His6 at BamHI-EcoRI sites. pJ4O16E7 was used for expression of E7 in mammalian cells (Storey et al., 1988) . The HPV-16 E7 mutants used in this study have all been described previously (Edmonds and Vousden, 1989; Banks et al., 1990; Barbosa et al., 1990; Massimi et al., 1997) .
Cells, transfections and CAT assays U2OS and Saos-2 cells were grown in DMEM supplemented with 10% foetal calf serum. Transfections were performed using standard calcium phosphate precipitation with 1 mg of reporter plasmid (unless otherwise stated) along with indicated amounts of expression plasmids. After 48 h cells were harvested and CAT assays performed as described previously (Pim et al., 1994) . Samples were analysed by thin layer chromatography and quanti®ed with a Packard Instant Imager (Packard, Meriden, CT, USA). BRK cell transformation assays were performed as described previously (Massimi et al., 1997) . Both the p31/32 and D52 ± 56 mutants of E7 were severely reduced in their respective abilities to cooperate with EJ-ras.
In vitro translations and GST-pull down assays 35 S-labelled proteins were produced in vitro by using a coupled transcription-translation system (TNT, Promega), according to the manufacturer's instructions. Fusion proteins were induced and puri®ed as described previously (Prathapam et al., 2001) . Equal amounts of GST and GST-E7 fusion protein bound to glutathione-linked agarose (Sigma) were incubated with the in vitro translated proteins for 1 h at room temperature in a buer containing 50 mM Tris HCl pH 7.5, 100 mM NaCl and 2.5 mM EDTA. Bound proteins were washed extensively in PBS containing 0.5% NP40 before analysis by SDS ± PAGE and autoradiography.
For the direct binding assay, histidine tagged HPV-16 E7 protein was puri®ed as described previously (KuÈ hne and Banks, 1998).
Western blotting
Proteins were separated by SDS ± PAGE and transferred to nitrocellulose. His 6 -16 E7 was detected by using a polyclonal antibody raised against the His-tagged HPV-16 E7, and then developed using the ECL detection system according to the manufacturer's instructions (Amersham).
